Psyched Wellness (PSYC.C) announced that they have completed extraction of AME-1 and have shipped it to their contract research organization in (CRO) partner labs in Asia.

The AME-1 was sent to the CRO in order to complete pre-clinical studies and other scientific work in the product development process. Psyched used ~20 kilograms of raw material was used to generate approximately 4.2 kilograms of AME-1, which represented the largest extraction of AME-1 to date.

The CRO plans on using the shipment to conduct a 90-day toxicity study, the neurobehavioral studies, the conditioned place preference test, and any other remaining scientific work that they need to do. By sending such a large amount of AME-1 to the CRO, they expand the amount of tests and research that they can conduct. This capability is especially useful when shipping to Asia, which takes more time and effort than shipping locally.

“We are extremely happy with the progress of our product development process and are pleased with the results that we are seeing,” said David Shisel, COO of Psyched Wellness. “Completing this extraction successfully was a very important milestone and the resulting material should be sufficient to complete the remainder of our pre-clinical work.”

AME-1 is an extract from the Amanita Muscaria, which has often been mislabelled as poisonous. However, through careful extraction, PSYC has managed to isolate Amanita Muscaria’s healing and restorative properties while eliminating the dangerous acid residues.

The 90-day toxicity study planned is not the first kind of study of this nature, as Psyched conducted similar tests back in April and May, when KGK Science conducted a 14-day oral toxicity study on AME-1, which they had said was in preparation for a 90-day oral toxicity study.

Psyched Wellness wants AME-1 to be the first Amanita Muscaria product out on the market, and they believe help to reduce stress, ease muscular tension, and promote restorative sleep. The work being conducted by the CRO is an integral part of the product development process in order to submit the AME-1 as a new dietary ingredient (NDI) in the United States and as a natural health product (NHP) in Canada.

“Psyched is a step closer to being able to bring our Amanita-based CPG products to market which are currently under development. We believe Amanita will have a sustainable commercial and societal impact, and we are passionate about creating products which will have the power to assist with stress relief, relaxation, and restful sleeping,” added Jeff Stevens, CEO of Psyched Wellness.

Following the news, Psyched Wellness shares are up half a cent and are currently trading at $0.205.